B8299
N-Butyldeoxynojirimycin
film (dried in situ), ≥98% (TLC)
Synonym(s):
Miglustat, NB-DNJ
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C10H21NO4
CAS Number:
Molecular Weight:
219.28
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.32
MDL number:
Product Name
N-Butyldeoxynojirimycin, film (dried in situ)
assay
≥98% (TLC)
Quality Level
form
film (dried in situ)
solubility
water: 9.80-10.20 mg/mL, clear, colorless
storage temp.
2-8°C
SMILES string
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
InChI
1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
InChI key
UQRORFVVSGFNRO-UTINFBMNSA-N
Gene Information
human ... UGCG(7357)
General description
N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.
Application
N-Butyldeoxynojirimycin has been used:
- in the inhibition of glycolipid synthesis in neuroblastoma cells
- in the inhibition the ceramide-specific glycosyltransferase in hepatocytes
- in the inhibition of β-glucosidase (GBA2) using fluorescence- activity assay in human embryonic kidney (HEK293) cells.
Biochem/physiol Actions
N-Butyldeoxynojirimycin is an inhibitor of glucosyltransferase and α-glucosidases. N-Butyldeoxynojirimycin, also known as misglustat, reduces glycolipid levels by substrate reduction therapy (SRT) and is effectively used for the treatment of glycosphingolipid lysosomal storage disorder, Gaucher disease.
α-glucosidase Inhibitor
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Beom Hee Lee et al.
Medicine, 96(45), e8492-e8492 (2017-11-16)
Gaucher disease (GD) is caused by a deficiency in the lysosomal enzyme glucocerebrosidase. Enzyme replacement therapy (ERT) is recommended for clinical improvement. The efficacy and safety of a new imiglucerase, Abcertin, were assessed in 7 Egyptian patients with treatment-naïve type
Cytoskeletal inhibitors, anti-adhesion molecule antibodies, and lectins inhibit hepatocyte spheroid formation
Nakamura M, et al.
Acta Medica Okayama, 56(1), 43-50 (2002)
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement
Cox TM, et al.
Journal of inherited metabolic disease, 26(6), 513-526 (2003)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| B8299-1MG | 04061826740996 |
| B8299-5MG | 04061833627846 |